

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ³ : A61K 31/60; C07C 101/74		A1 -	(11) International Publication Number: WO 81/02671 (43) International Publication Date: 1 October 1981 (01.10.81)
(21) International Application Number: PCT/DK81/00027 (22) International Filing Date: 20 March 1981 (20.03.81) (31) Priority Application Number: 1202/80 (32) Priority Date: 20 March 1980 (20.03.80) (33) Priority Country: DK (71) Applicant (for all designated States except US): FARMA- CEUTISK LABORATORIUM FERRING A/S [DK/ DK]; Indertofte 5, DK-2720 Vanløse (DK). (72) Inventor; and (75) Inventor/Applicant (for US only): HALSKOV, Søren [DK/DK]; Granvænget 3, DK-3200 Helsingør (DK).		(74) Agent: HOFMAN-BANG & BOUTARD; Adelgade 15, DK-1304 Copenhagen K (DK). (81) Designated States: DE, DK, GB, JP, NL, SU (Inventor's certificate), US. Published With international search report Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments	

(54) Title: PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF COLITIS ULCEROSA AND CROHN'S DISEASE BY ORAL ADMINISTRATION

ILEOSTOMY STUDIES - INDIVIDUAL SUBJECTS



(57) Abstract

A pharmaceutical composition containing as active ingredient 5-aminosalicylic acid or a pharmaceutically acceptable salt or ester thereof allows the treatment of colitis ulcerosa or Crohn's disease by oral administration. A particular slow-release tablet formulation and its preparation are disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	KP	Democratic People's Republic of Korea
AU	Australia	LI	Liechtenstein
BR	Brazil	LU	Luxembourg
CF	Central African Republic	MC	Monaco
CG	Congo	MG	Madagascar
CH	Switzerland	MW	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SE	Sweden
FR	France	SN	Senegal
GA	Gabon	SU	Soviet Union
GB	United Kingdom	TD	Chad
HU	Hungary	TG	Togo
JP	Japan	US	United States of America

Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration

5

The present invention relates to a pharmaceutical composition useful for the treatment of colitis ulcerosa and Crohn's disease, currently denominated "inflammatory bowel diseases" (IBD). The invention also relates to a method for the treatment of IBD.

10

Colitis ulcerosa is a chronic inflammatory disease of the colon of unknown etiology. In its acute stages it resembles an infectious disease, but no microorganism has been definitively established as its cause. The disease causes inflammations of the mucosa of the colon, with extension to the submucosa in severe cases. Typically, not only the colon, but also the rectum is attacked, but only rarely is the ileum involved. The ulcer formation and its extent vary with the developmental stage of the disease, but can often be detected macroscopically (sigmoidoscopy and colonoscopy). For an exhaustive discussion of the disease and the various surgical and medical methods of treatment reference is made to "Ulcerative colitis", Goodman & Sparberg, Wiley, New York 1978.

20

25

The related disease, Crohn's disease, also known as regional enteritis or colitis granulomatosa, which is also discussed by Goodman & Sparberg, is most frequently located in the small intestine (small bowel), especially in the ileum, but may also affect the jejunum and any part of the colon, including the rectum. In the latter case the differentiation of Crohn's disease from ulcerative colitis give rise to great diagnostic problems. Generally, the inflammatory reactions differ

30

35



from that of colitis ulcerosa by progressing to layers deeper than the mucosa and affecting the epithelium in a lesser degree.

- 5 A thorough review of the state of the art with regard to both diseases are given by J.B. Kirsner, JAMA, Feb. 8, 1980, vol. 243, No. 6.

- Both diseases have become increasingly frequent
10 especially in the developed countries, and it is estimated that the number of IBD patients in the United States alone exceed 500,000 people, and that the figures continue to increase (Goodman & Sparberg). Therefore, treatment of IBD has become one of the most important
15 problems of modern medicine.

- The medical treatment will be further expounded below, but it should briefly be mentioned that failure to respond to medical treatment invariably necessitates
20 surgery, where the standard surgical operation in the treatment of ulcerative colitis is total proctocolectomy (removal of the colon and rectum) with a permanent ileostomy. According to Kirsner, op. cit. 15 to 20% of the patients with colitis ulcerosa require surgical
25 intervention, while the figure in case of Crohn's disease is as high as 40 or 50%.


- It is therefore evident that any improvement in the effect of the medical treatment would offer considerable
30 advantages.

- Common drugs for medical treatment of colitis ulcerosa and Crohn's disease are corticosteroids, e.g. prednisone, prednisolone and hydrocortisone. A drug recently pro-
35 posed is 6 α -fluoro-11 β -hydroxy-3,20-dioxo-16 α -methyl-1,4-pregnadiene-21-carboxylic acid butyl ester, cf.



PCT Application No. WO 80/00122.

Another drug which has been used for years, especially
in the treatment of colitis ulcerosa, is sulfazalazine
5 (salicylazosulfapyridine, SASP) consisting of sulfa-
pyridine (SP) and 5-aminosalicylic acid (5-ASA)
coupled via an azo-bond. The mode of action of SASP
is unknown (Azad Khan et al., Lancet, 2, 1977, p. 892-
895), but it has been shown that when sulfazalazine is
10 taken by mouth, the ordinary mode of administration,
it reaches the colon intact where it is split by
bacteria into SP and 5-ASA, cf. the following reaction
scheme:



25 So far it has chiefly been assumed that the effect of
the drug was primarily due to a topical action on the
ulcer sites, Peppercorn and Goldman, Gastroenterology
64, 1973, p. 240-245, but there is still no consensus
among researchers whether the effect should be ascribed
30 to the coupling product SASP or one or both of the
moieties SP and 5-ASA. One of the difficulties is the
limited clinical examination material so that the
statistical reliability of the reported results is
open to discussion.

35

An important contribution to the knowledge in this field



was made by Azad Khan et al., op. cit., who compared SASP, SP and 5-ASA administered rectally and concluded that the therapeutically active moiety was 5-ASA and that SP only acts as a "carrier" to ensure that 5-ASA is not released until it has reached the colon. Azad Khan chose rectal administration and not oral administration, which is the ordinary mode for SASP, because previous studies of absorption in healthy patients had shown that free 5-ASA is absorbed from the small bowel in particular the jejunum, which was considered inappropriate as it prevented topical action in the colon.

This same point of view is held by Willoughby et al., Scand. J. Gastroent. 1980, 15, 715-719, who undertook enema studies on the derivative N-acetyl-5-aminosalicylic acid (5-AcASA). They concluded that 5-AcASA resembled 5-ASA in its effect on the inflamed mucosa in ulcerative colitis, but that neither were suitable as oral agent. Instead they suggested further studies into substituted salicylates.

Consistently therewith J.B. Kirsner, op. cit., in his review article concludes that therapeutic hopes for the future amongst other things include the combination of 5-ASA with a carrier molecule that is less toxic than sulfapyridine.

The work of Azad Khan et al., which has been confirmed by van Hees et al., Lancet, 1, 1978, p. 277, has not carried enough conviction to prevent Fischer and Klotz, J. Chromatography, 162 (1979), p. 237-243 from stating that till now SP has been considered the biologically active moiety of SASP, but that said two works have shown that 5-ASA also has therapeutic effect, so plasma concentration measurements of 5-ASA and its major



metabolite 5-acetylamino salicylic acid (5-AcASA) might be of some help in increasing the therapeutic efficacy of SASP and evaluating its mechanism of activity.

5 It should be mentioned that while it has been demonstrated that SP is highly absorbed from the colon and then metabolized by acetylation and glucuronidation in the liver before it is excreted in the urine, the major
10 part of the released 5-ASA is not absorbed but excreted in the feces, partly as 5-ASA and partly as 5-AcASA (Peppercorn & Goldman, op. cit., Azad Khan, op. cit., and van Hees et al., Gut, 1979, 20, p. 300-304), a
15 minor portion being excreted in the urine in the form of the metabolite 5-AcASA. The amount excreted in the urine varies from about 15% to 35% in said articles, where in several cases only healthy patients have been
20 examined since the primary object was to study the mechanisms of absorption. However, it must be assumed that precisely the huge difference in absorption of SP and 5-ASA is one of the reasons why several researchers still believe that SP has its share of the responsibility for the effects of SASP.

Though Azad Khan thus found that 5-ASA when administered
25 rectally exhibits a useful therapeutic activity like SASP, he excludes oral administration, and having observed a considerable instability of 5-ASA in aqueous suspension he proposes to synthesize a new compound without these drawbacks. The disadvantages of SASP as
30 such include a plurality of side effects, such as nausea and vomiting, skin rashes, anemia, arthralgias, headache, etc., cf. Goodman and Sparberg, op. cit. which in case of severe attacks of colitis ulcerosa have inhibited the use of desirably high doses, which has made it
35 necessary to combine the treatment with administration of corticosteroids with their well-known drawbacks.



Another serious disadvantage is that a considerable amount of the patients (up to 10%) are allergic to sulfa drugs, thereby excluding SASP treatment.

- 5 Conclusively, it might therefore be said that experts agree in the desirability of providing a drug with improved activity over SASP, and in the possibility of achieving such improvement with 5-ASA as starting point. However, opinions are divided as to the significance of
- 10 5-ASA, and it is considered inappropriate to use this compound because of its instability and because it is absorbed before it reaches the colon if it is administered orally. If, however, the problems of stability could be solved it should be possible to use the compound
- 15 in rectal drugs.

- The object of the present invention is to provide an improved pharmaceutical composition useful for the treatment of colitis ulcerosa or Crohn's disease by
- 20 oral administration and a method for such treatment.

- The invention is based on the fact that the rooted prejudice against oral administration of 5-ASA as free acid has surprisingly been overcome because in
- 25 this mode, too, 5-ASA and its salts and esters have a useful therapeutic effect on colitis ulcerosa, in particular when administered in the form of sustained-release tablets.

- 30 Accordingly the invention relates to a pharmaceutical composition useful for the treatment of Colitis ulcerosa or Crohn's disease by oral administration, which comprises as essential active ingredient an effective amount of 5-aminosalicylic acid or a pharmaceutically
- 35 acceptable salt or ester thereof in admixture with a pharmaceutically acceptable carrier.



The salts of 5-ASA may be acid addition salts, in particular the hydrochloride, but any pharmaceutically acceptable, non-toxic organic or inorganic acid may be used.

- 5 Also salts formed with the carboxylic acid group may be used. As examples may be mentioned alkali metal salts (K, Na), alkaline earth metal salts (Ca, Mg), but again any pharmaceutically acceptable, non-toxic salt may be used. The Na- and Ca-salts are preferred.

10

- In Danish patent appln. no. 1250/77, available to public inspection and being incorporated herein by reference, a number of esters of ortho-, meta- and para-salicylic acid are disclosed. Said esters are effective as ultra-
15 violet ray screening compounds thereby rendering themselves useful in preventing solar burning. The disclosed meta- (or 5-) aminosalicylic esters and a number of related esters are also applicable in the composition according to the invention.

20

Applicable esters are e.g.


- straight chain or branched C_1 - C_{18} alkyl esters,
e.g. methyl, ethyl, propyl, isopropyl, butyl, iso-
25 butyl, amyl, hexyl, heptyl, octyl, nonyl, decyl, lauryl, myristyl, cetyl, and stearyl, etc.,

- straight chain or branched C_2 - C_{18} alkenyl esters,
e.g. vinyl, allyl, undecenyl, oleyl, linolenyl, etc.,

30

C_3 - C_8 cycloalkyl esters, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, etc.,

- 35 aryl esters, e.g. phenyl, toluyl, xylyl, naphthyl, etc.,



alicyclic esters, e.g. menthyl, etc., or

aralkyl esters, e.g. benzyl, phenethyl, etc.


- 5 Generally speaking the proper selection of the active ingredient depends on the selected type of formulation, the disease pattern, especially the site and type of the disease, and the desired release of the active ingredient, as shall be further expounded below
10 together with the concept "effective amount".

The physical state and solubility characteristics of the 5-ASA derivatives must be taken into account when selecting a suitable carrier composition for the
15 ingredient.


The preferred active ingredient at present is the free acid, 5-aminosalicylic acid.

- 20 In the previous oral administrations of 5-ASA only the mechanism of absorption was examined, and it was concluded that the compound is essentially completely absorbed from the small bowel, as no noticeable amounts of 5-ASA or 5-AcASA were observed in the feces. The
25 studies were exclusively made in animals (rats), cf. Peppercorn and Goldman, Gastroenterology 64, 1973, p. 240-45, or in healthy volunteers (Schröder and Campbell, Clin. Pharm. and Ther. vol. 13, No. 4, 1972). The effect of SASP was, as mentioned, believed to be
30 caused by topical action (Peppercorn et al., op. cit.) and accordingly no material on a possible effect of 5-ASA per os is available.

Without tying it down to any specific theory, it is
35 believed that owing to three reactive groups -COOH, -OH and -NH₂, 5-ASA establishes hydrogen bonds to the



- linear proteins in connective tissues, i.a. in the colon, and thereby exerts a kind of a "depot effect" on colitis ulcerosa. This seems to be in good harmony with Fischer and Klotz, J. Chromatography 162 (1979) p. 237-243, who demonstrated very low serum concentrations of 5-ASA and its metabolization product 5-AcASA by plasma concentration measurements after oral administration of 4 g of SASP.
- 10 A particularly interesting aspect of the invention is the use of the composition in the treatment of Crohn's disease. In this respect SASP has not proved to be very effective, at least not in the most frequent case, where the disease is limited to the ileum. Reference is made to Peppercorn and Goldman, op. cit. p. 244, van Hees et al., Gut 1979, op. cit. p. 300, Kirsner, op. cit., p. 559 and Klotz et al., New Engl. J. of Med. 303, No. 26, dec. 1980. This is probably due to the above-mentioned fact that SASP is not split under release of 5-ASA until it reaches the colon. In the less frequent case, where Crohn's disease also extends to or is limited to the colon and rectum, SASP has proved effective, but of course accompanied by its well-known side effects.
- 25 As shown below in clinical tests on ileostomy patients up to 50% of the 5-ASA administered in the form of a composition according to the invention may be absorbed from the small bowel thereby rendering an effect on Crohn's disease highly probable.
- 30



In addition to the obvious advantages for the patients offered by oral administration rather than rectal, e.g. by way of retention enemas, oral administration of 5-ASA has a significantly advantage in terms of effect.

5 For van Hees et al., Gut, 1979, 20, 300-304 (op. cit.) has demonstrated that the absorption of 5-ASA from the colon following administration of SASP is drastically decreased in case of diarrhoea which frequently accompanies colitis ulcerosa, in particular in severe

10 cases.


The effective oral dose depends on the extent of the disease and for adults it usually amounts to 0.5 to 1.0 g twice a day. Generally about 20 mg/kg body weight

15 of 5-ASA or a salt or ester thereof (calculated as 5-ASA) will be the recommended initial daily dosage subject to adjustment in accordance with the observed results of the treatment. In particular the dosage for children should be adjusted by means of serum

20 concentration measurements.

5-ASA and its derivatives can be formulated as ordinary oral drugs such as tablets or capsules by admixture with suitable pharmaceutical carriers which are well-

25 known to the artisan, e.g. lactose, maize starch, potato starch, and lubricants, e.g. magnesium stearate and talc. A preferred carrier constituent is a micro-crystalline cellulose having approximately the same



density as 5-ASA thereby preventing sedimentation and resulting heterogeneity during tablet production. Generally, tablets in the form of slow-release tablets are preferred, but also enterosoluble tablets may be used.

5

A particularly advantageous slow-release tablet has been developed the preparation of which is illustrated in the following non-limiting example, based on the production of 1000 tablets containing 250 mg of the active ingredient. (All ingredients pharmaceutical grade).

10

EXAMPLE

15 Preparation of granulate I

250 g of 5-ASA are granulated to a particle size of from 0.7 - 1 mm with 25 g of polyvinylpyrrolidone dissolved in isopropanol (1:9 w/w). Upon evaporation of the isopropanol the resulting dry granulate is sprayed with 45 g of ethyl cellulose dissolved in acetone (3:97 w/w) resulting in granulate particles individually coated with ethyl cellulose upon evaporation of the acetone.

20


25 Preparation of granulate II

270 g of microcrystalline cellulose and 60 g of potato starch are granulated with about 33 g of the above polyvinylpyrrolidone solution to the same particle size.

30

The resulting about 320 g of the coated granulate I are mixed with a lubricant mixture of 3 g of sodium stearate and 27 g of talc and with dry granulate II to form 650 g of total granulate which are pressed to form tablets with a diameter of 13.5 mm and a weight of 650 mg/tablet containing 250 mg of 5-ASA.

35



The resulting tablets were used in the clinical tests described below. As shown in the tests with ileostomy patients about 50% of the active ingredient is released in the small bowel, the remainder being available to
5 the colon. By controlling the release a preparation with predominant effect versus Crohn's disease or colitis ulcerosa according to the site of the disease of the individual patient can be obtained. The above formulation is believed to represent an effective com-
10 promise applicable versus both diseases.

Generally the release can be controlled by varying one or more of the following:

- 15 a) The particle size of the granulated active ingredient.
 - b) The thickness and permeability (swelling properties) of the coating.
 - 20 c) The active ingredient proper.
 - d) The pH-conditions within the coated particle.
- 25 Thus in case of Crohn's disease, where an early release of the active ingredient in the small bowel is desirable, one may select a relatively small particle size, e.g. about 0.7 mm or less and a relatively thin coating, e.g. by lowering the ethyl cellulose amount used or select
30 a more permeable coating material, and an active ingredient with a good solubility at pH 7.5 which is the prevailing pH in the small bowel.

In case of colitis ulcerosa, where a delayed release
35 of the active ingredient until the colon is reached



is desirable, one may select an active ingredient having a good solubility at pH 6 which is the prevailing pH in the colon and a greater particle size, e.g. about 1 mm or more, and a relatively thick coating.

5

The most effective composition of the tablet taking the individual patient's disease pattern into account can be found by routine tests once the pharmaco-kinetic relationships are more clearly established.

10

In particular the solubility, acidity, and susceptibility to hydrolysis of the different derivatives of 5-ASA, such as acid addition salts, salts formed with the carboxylic group, e.g. alkali metal salts, alkaline earth metal salts, etc., and esters, e.g. alkyl, alkenyl, aryl, aralkyl, cycloalkyl esters, etc., under different pH conditions may be used as guidelines for the proper choice. Also suitable pH-conditions might be established within the coated particles by adding to granulate I besides the active ingredient a suitable buffer in accordance with the desired release pattern.

20

The invention also relates to a method for the preparation of a sustained release tablet as defined in claim 9.

25

Besides the above-mentioned variations in order to obtain the desired release the tablet ingredients may also be varied. While the preferred organic solvent for the polyvinylpyrrolidone is isopropanol, other organic solvents may also be used, as long as they do not in a significant degree act as solvents for the selected 5-ASA derivative.

30

While the preferred coating agent is ethyl cellulose

35



other coating agents may also be used, provided they secure the desired release pattern. In particular a number of other cellulose derivatives must be assumed to be applicable.

5

Depending on the selected active ingredient one may also depart from the proportions laid down in claim 9 and the example. In particular one may leave out Granulate II or substitute for Granulate II a conventional pharmaceutical tablet carrier, provided that the active ingredient has the necessary stability.

10

Clinical test results

15 Before subjecting 5-ASA to clinical tests animal studies were carried out.

Toxicity test

20 The acute toxicity in rats and mice was examined in accordance with the directions of Ph. Nord.

No toxic reactions were observed when 5-ASA was administered intravenously in doses up to 500 mg/kg in mice and up to 200 mg/kg in rats.

25

It is the purpose of the clinical studies described below to estimate the bioavailability of a sustained-release type 5-ASA tablet (Pentasa®) of the composi-

30



tion described above in the example by the study of 5-ASA/
5-AcASA plasma levels in healthy volunteers as well
as the excretion pattern in urine and feces.

- 5 Furthermore the availability of 5-ASA for the small
bowel alone was investigated in the ileostomy effluents
of a group of patients.

METHODS AND MATERIALS

10

5-ASA tablet

- A sustained-release type tablet containing 250 mg of
5-ASA (Pentasa[®]). Only trace amounts of 5-ASA are
released in the stomach at normal gastric pH. At pH 7.5
15 as is usual in the jejunum 5-ASA was released linearly
in relation to time, all 5-ASA being released in 12
hours. At pH 6, the usual acidity of the colon, the
release of 5-ASA from the tablet, was reduced. This
unforeseeable and surprising release pattern should
20 in principle ensure a continuous release of 5-ASA
through the whole length of colon.

Determination of 5-ASA and 5-AcASA in biological fluids

- Procedures for the determination of 5-ASA and 5-AcASA in
25 ileostomy effluents, feces, urine and blood were based
on a newly developed HPLC assay combined with fluorescence
spectrophotometry. The detection limit of the procedure
was found to be less than 0.03 mg of 5-ASA/ml in bio-
logical fluids.

30

SUBJECTS STUDIED

Ileostomy patients

- Six ileostomy patients colectomized because of colitis
35 ulcerosa with intact small bowel were studied. Their
distribution as to sex, age, height, body weight,

RECEIVED
CIP
1981

time since colectomy, small bowel transit time (carmine), and acetylator phenotype (v. Fischer and Klotz, op. cit.) (assessed by sulphadimidine) are shown below in table I.

5

Healthy volunteers

Fourteen healthy persons consented to volunteer. They had no previous or present symptoms or signs of gastrointestinal or other disease apart from uncomplicated
10 appendectomy. There were seven females and seven males. Mean age and age range were for the women 32.4 years and 29-37 years, and for the males 32 years and 24-40 years, respectively. Mean body weight and weight range were for the females 58.6 kg and 53-67 kg, and for the
15 males 70.9 kg and 60-83 kg, respectively. There were eight slow and 6 fast acetylators. Their biographical data are shown in table II below.

STUDY PLAN

20

Ileostomy patients

A single dose of two tablets of sustained-release 5-ASA, i.e. total dose 500 mg, were ingested at 8 a.m. by the fasting patient who thereafter took a normal continental
25 breakfast, lunch at noon, and dinner at 6 p.m. Ileostomy effluents were collected every hour for eight hours (fig.1+2) urine was collected over an 8 hour period and venous blood was drawn at intervals through the first eight hours (figs. 3 and 4).

30

Volunteers

Each subject took two 5-ASA tablets, i.e. 500 mg 5-ASA, three times a day for six days, at 8 a.m., 4 p.m. and at midnight except for the first day, where the two first
35 ingestions took place at 9 a.m. and 5 p.m. The injections are shown by arrows on fig. 5 and 6.

The two tablets at 8 a.m. were taken by the fasting subject. Venous blood samples for determination of 5-ASA and 5-AcASA were drawn at intervals throughout the first day (fig. 5) and at 7.50 the following five days (i.e. before the 8 a.m. tablets were ingested) (fig. 6). Twenty-four hour urine and faecal samples were collected on the 6th day for quantitative determination of 5-ASA and 5-AcASA. Every day throughout the study period of six days a single faecal sample was analyzed qualitatively for the presence of 5-ASA and 5-AcASA.

SAFETY MONITORING

In both parts of the study, ileostomy patients as well as the healthy volunteers filled in diary sheets concerning specified signs and symptoms (nausea, vomiting, headache, dizziness, visual and auditory sensations, abdominal pain or discomfort, constipation, diarrhoea, muscle-joint sensations and skin manifestations). Blood pressure and pulse rate were monitored and on - as well as off - study analysis of hemoglobin, reticulocytes, thrombocytes, leucocytes, coagulation factors, S-alamine-amino-transferases, Se-urea, S-Creatinin together with urine analysis for albumin, glucose and sediment were carried out.

ETHICS

All participants in the study were informed about the background, goals and procedures by oral and written instructions. Informed consent by signature was obtained in all cases.




Table I - Biographical data for the six ileostomy patients

No.	Sex	Age years	Ileostomy age years	Height cm	Body weight kg	Small bowel transit time hours	Acetylalator phenotype
1	f	47	4 1/2	166	70	4 1/4	slow (0.33)
2	f	47	3	169	60	2 3/4	slow (0.24)
3	m	19	1/2	182	83	5 1/2	slow (0.27)
4	m	23	5	190	81	4 1/2	slow (0.33)
5	m	23	2	178	80	4 3/4	fast (0.81)
6	f	21	1 1/2	167	57	3 1/2	slow (0.26)
N = 6 3 f 3 m							5 slow 1 fast
Mean	f	22.7	3.0	167	62.3	3 1/2	
Mean	m	21.7	2 1/2	183	81.3	5	
Mean total		22.2	2 3/4	175	71.8	4 1/4	

Tabel II - Biographical data for healthy human volunteers

No.	Sex	Age years	Height cm	Body weight kg	Acetylator phenotype
1	m	33	185	78	slow (0.30)
2	f	34	158	54	slow (0.25)
3	m	31	178	64	fast (0.76)
4	f	29	169	57	slow (0.21)
5	m	35	182	83	slow (0.24)
6	f	32	167	53	slow (0.32)
7	m	27	182	75	slow (0.22)
8	f	30	176	67	fast (0.70)
9	m	24	178	65	fast (0.73)
10	f	30	160	56	fast (0.85)
11	m	40	178	71	fast (0.71)
12	f	35	168	58	slow (0.23)
13	m	34	182	60	slow (0.33)
14	f	37	169	65	fast (0.66)

7 m
7 f

slow 8
fast 6

Mean	f	32.4	166.7	58.6
Mean	m	32.0	180.7	70.9
Mean total		32.2	173.7	64.7



RESULTSIleostomy patients

A cumulative excretion rate of 5-ASA and 5-AcASA via
5 ileostomy effluents from the individual subjects is
shown in fig. 1. Fig. 2 illustrates the ratios between
free 5-ASA and 5-AcASA in the ileostomy secretions
and 5-ASA still retained in the granules of the
sustained-release preparation based on the mean values
10 from fig. 1. From the figures is seen that no 5-ASA
or 5-AcASA could be detected in ileostomy secretions
during the first two hours. During the following hours
free 5-ASA and 5-AcASA were registered in the effluents
as they were excreted at constant rates up to 8 hours
15 after ingestion of the tablets. At that time 58%
of the ingested total dose was collected in the
ileostomy bags. This portion was equally distributed
among three parts: one third as free 5-ASA, another
third as free 5-AcASA and the last third as 5-ASA
20 still retained in the granules. However, in three of
the subjects the collecting time was expanded further
up to 48 hours after ingestion (see fig. 1). In one of
these a further 20% 5-ASA was found indicating that more
than one third of the 5-ASA was retained in the granules
25 in this patient.

In the blood plasma the concentrations measured during
the study are shown in fig. 3 (individual values) and
fig. 4 (mean values. Bars indicate total ranges).
30 Before ingestion of 5-ASA plasma concentrations were
zero in all six cases. Trace amounts of 5-AcASA were
found half an hour after ingestions. Peak concentra-
tions of 5-AcASA amounted to 0.5 - 1.4 $\mu\text{g/ml}$ within
an interval of 2 - 5 hours after ingestion of 5-ASA.



In the urine collected no 5-ASA was found except in one case where 1.4 mg 5-ASA was found. Within 8 hours after ingestion of 5-ASA a mean of 60 mg 5-AcASA was found, ranging from 42 - 82 mg. This corresponds to a mean of 12% and a range from 8 - 16% of the ingested dose, respectively.

No signs or symptoms and no change in results of biochemical examination of blood or urinary control parameters indicated any untoward symptomatic or toxic effect of the ingested drug.

Normal healthy volunteers

As was found in the series of ileostomy patients, in this part of the study where fourteen subjects took sustained-release 5-ASA (Pentasa®) 500 mg t.i.d. for six days, no 5-ASA or 5-AcASA was detected the morning of day one before ingestion of 5-ASA. Similarly, during the whole study, only 5-AcASA was detected in plasma and urine. Variations of plasma concentrations of 5-AcASA are shown in figs. 5 and 6. The indicated values represent mean values of 14 observations \pm 2 SEM (95% confidence limit). After ingestion of the first dose of 500 mg 5-ASA on day one a rise in plasma concentration of 5-AcASA similar to the values found in the ileostomy patients is observed, rising to a mean value of 1.3 μ g/ml - Thereafter a fall is registered and then following ingestion of a second dose of 5-ASA another rise up to a little higher values, resulting in a mean value of 1.6 μ g/ml three hours after ingestion of the second dose (see fig. 5). During the following days up to day 5 the mean values are slowly increasing up to a level of about 1.8 μ g/ml, as seen from fig. 6. This level, corresponding to a 95% confidence interval of the mean from 1.7 to 2.2 μ g/ml is maintained day

RECEIVED
FBI
JAN 15 1982

6 indicating that steady state levels are reached. The total range of 5-AcASA plasma concentrations in all fourteen subjects on day six was from 1.20 - 2.83 μ g/ml.

- 5 Urinary excretions of free 5-ASA could not be recorded. On day 6, in steady state, a mean of 737 mg 5-AcASA was excreted during 24 h (calculated as 5-ASA). The excretions ranged from 447 to 1304 mg per 24 h. The 95% confidence limits of the mean value of 5-AcASA
10 excretions were 587 - 887 mg per 24 h.

- In faeces a daily qualitative analysis showed presence of 5-ASA and 5-AcASA in morning samples from day 2 throughout the study. Quantitative analysis on day 6,
15 in steady state, showed a total mean faecal excretion of free 5-ASA and 5-AcASA of 514 mg per 24 h, a range from 84 to 877 mg and 95% confidence limits of the mean excretion of 378 - 650 mg per 24 h.

- 20 Thus in steady state condition on day 6 the mean recovery rate (daily ingested total dose 1500 mg 5-ASA) was 83%.


- Also an analysis was made in an attempt to establish the faecal content of granules. However, the analysis was
25 not carried out until 24 hours after the collection of the faeces, which means that some of the granules have released their content of 5-ASA. The average total of 5-10% therefore accounts for both released and non-released 5-ASA. The important thing is that in case of patients
30 instead of healthy volunteers the 5-ASA would have been available in the colon.

- The tests did not show a significant variation according to differences in acetylator phenotype (slow and fast
35 acetylators) indicating that the acetylation does not only take place in the liver but also in the tissues.

5-ASA
10
15

No results of analysis of control parameters pointed toward any untoward side effect, this being as to symptoms, signs, biochemical analysis or examinations of urinary sediments. In this part of the study these
5 examinations were repeated at an interval of 1 - 2 weeks after conclusion of the study.

In conclusion, the above studies seem to indicate that the sustained-release 5-ASA (Pentasa®) is a suitable
10 preparation for the treatment of colitis ulcerosa as well as of Crohn's disease, including cases with small bowel affection.



P a t e n t C l a i m s

1. A pharmaceutical composition useful for the treatment of colitis ulcerosa or Crohn's disease by oral
5 administration, which comprises as essential active ingredient an effective amount of 5-aminosalicylic acid or a pharmaceutically acceptable salt or ester thereof in admixture with a pharmaceutically acceptable carrier.
- 10 2. The composition according to claim 1, wherein the salt is an addition salt with an organic or inorganic acid.
3. The composition according to claim 2, wherein the
15 acid addition salt is the hydrochloride.
4. The composition according to claim 1, wherein the salt is an alkali metal or alkaline earth metal 5-aminosalicylate.
- 20 5. The composition according to claim 1, wherein the ester is selected from the group consisting of straight chain or branched C_1 - C_{18} alkyl esters, straight chain or branched C_2 - C_{18} alkenyl esters, C_3 - C_8 cycloalkyl
25 esters, aryl esters, aralkyl esters, and alicyclic esters.
6. The composition according to claim 1 having the form of a sustained-release tablet.
- 30 7. A composition according to claim 6, comprising as an essential active ingredient an effective amount of 5-aminosalicylic acid or a pharmaceutically acceptable salt or ester thereof in admixture with an orally
35 administerable pharmaceutical carrier, said active ingredient being in the form of particles coated



with a pharmaceutically acceptable coating material which will gradually release the active ingredient after oral administration upon arrival at the small intestine.

5

8. A sustained-release tablet according to claim 7, wherein the coating material is ethyl cellulose.

9. A method for the preparation of sustained-release
10 tablets useful for the treatment of colitis ulcerosa or Crohn's disease, comprising the steps of

a) preparing a first granulate from 5-aminosalicylic acid or a pharmaceutically acceptable salt or ester
15 thereof and about 10% by weight (solids content, based on the 5-aminosalicylic acid) of a polyvinylpyrrolidone-containing solution in an organic solvent, preferably isopropanol, thereby to provide granules of a particle size from about 0.7 to 1 mm, upon evaporation of the
20 solvent,

b) applying onto said granules a coating composition, comprising a solution in an organic solvent, preferably acetone, of a pharmaceutically acceptable coating
25 material which will gradually release the active ingredient upon arrival at the small intestine, thereby to provide coated granules upon evaporation of the solvent,

30 c) optionally preparing a second granulate of about : same particle size as the first granulate from a pharmaceutical carrier having essentially the same density as the 5-ASA derivative and about 10% by weight of a polyvinylpyrrolidone solution in an organic
35 solvent.



d) mixing the first granulate with about 5% by weight, calculated on the total solids content of a lubricant and optionally the second granulate or a conventional pharmaceutical tablet carrier in an amount in accordance
5 with the desired size and active ingredient content of the tablet,

e) forming tablets from the resulting mixture in a manner known per se.

10

10. A method according to claim 8, wherein the coating material is a cellulose derivative, preferably ethyl cellulose.

15 11. A method for the treatment of colitis ulcerosa or Crohn's disease comprising orally administering an effective amount of a composition having as the essential active ingredient 5-aminosalicylic acid or a pharmaceutically acceptable salt or ester thereof.

20

12. A method for the treatment of colitis ulcerosa or Crohn's disease comprising orally administering an effective amount of a composition having as the essential active ingredient 5-aminosalicylic acid or
25 a pharmaceutically acceptable salt or ester thereof in admixture with an orally administerable pharmaceutical carrier.


13. The method of claim 11 in which said composition
30 is in the form of a sustained-release tablet.

14. The method of claim 13, in which said tablet comprises the active ingredient in the form of particles coated with a pharmaceutically acceptable coating
35 material which will gradually release the active ingredient after oral administration.



15. The method of claim 12, in which the administered composition is a sustained-release tablet prepared according to claim 9.






2/6

FIG. 2


ILEOSTOMY STUDIES - MEAN VALUES, N=6



3/6


FIG. 3

ILEOSTOMY STUDIES - 5-AcASA IN PLASMA - INDIVIDUAL SUBJECTS



4/6

FIG. 4
ILEOSTOMY STUDIES - 5-AcASA IN PLASMA
MEAN VALUES, N=6



5/6

FIG. 5

HEALTHY VOLUNTEERS -- 5-ACASA IN PLASMA -- DAY 1
MEAN VALUES, N=14





FIG. 6

HEALTHY VOLUNTEERS - 5-ACASA IN PLASMA
MEAN VALUES, N=14



6/6



INTERNATIONAL SEARCH REPORT

International Application No PCT/DK81/00027

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC 3		
A 61 K 31/60, C 07 C 101/74		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
IPC 3	A 61 K 31/235, 31/24, 31/60, 9/00, 9/20, 9/22, 9/36, 9/48, C 07 C 101/74	
IPC 1	A 61 k 27/00, 9/04, 3/00 .../...	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
SE, NO, DK, FI classes as above		
III. DOCUMENTS CONSIDERED TO BE RELEVANT **		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
X	CH, A, 342 965 published 1960, January 30, W Daniewski.	1-3
X	GB, A, 722 795 published 1955, February 2, see inter alia page 1, lines 10-15 and Example 3, Rheinpreussen Aktiengesellschaft Fuer Bergbau und Chemie.	1
X	GB, A, 2 021 409 published 1979, December 5; see inter alia page 1, lines 119-127, page 3, lines 54-59 and page 4, lines 1-76, Fisons Limited.	1-10
X	DE, A, 2 712 934 published 1978, October 5, see inter alia page 16 and Example 13, Mundipharma AG	1,5
A	FR, A, 2 267 088 published 1975, November 7, see Example 17, Auburn Research Foundation.	1
.../...		
<p>* Special categories of cited documents: **</p> <p>"A" document defining the general state of the art</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document cited for special reason other than those referred to in the other categories</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but on or after the priority date claimed</p> <p>"T" later document published on or after the international filing date or priority date and not in conflict with the application, but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search *		Date of Mailing of this International Search Report *
1981-07-15		1981-07-20
International Searching Authority *		Signature of Authorized Officer **
Swedish Patent Office		<i>Martin Hjalmdahl</i> Martin Hjalmdahl

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

II National Cl US Cl	<u>Continuation Fields Searched</u> 30h:2/36, 9/02, 9/03, 12q:34 <u>260:471, 519; 424:230; 560:23; 562:453</u>	
------------------------------------	--	--

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹⁰

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 11-15, because they relate to subject matter ¹² not required to be searched by this Authority, namely:

Methods for treatment of the human or animal body by therapy.

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ¹¹

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
X	The Lancet, issued 1977, October 29, (London), A.K. Azad Khan et al. "An experiment to determine the active therapeutic moiety of sulphasalazine", see pages 892-895.	1
X	Journal of Pharmaceutical Sciences, Volume 68, no. 10, issued 1979, October (Washington), H.J. Pieniaszek, Jr, and T.R. Bates, "Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats", see pages 1323-1325.	1
A	Gastroenterology, Volume 64, no. 2, issued 1973 (Baltimore), M.A. Peppercorn and P. Goldman, "Distribution studies of salizylazosulfapyridine and its metabolites", see pages 240-245, especially page 241.	1
PX	Scandinavian Journal of Gastroenterology, Volume 15, no. 6, issued 1980, September (Oslo), C.P. Willoughby et al., "The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis", see pages 715-719.	1